Mogling Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mogling Bio is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, USA, targeting the biology of aging. The company's core technology platform focuses on inhibiting the age-associated overactivation of the Cdc42 GTPase protein to rejuvenate stem cell function and combat a range of age-related conditions. Backed by seed investment from Kizoo Technology Capital and an exclusive license for its lead asset CASIN from Cincinnati Children's Hospital, Mogling Bio is positioned at the intersection of aging biology and regenerative medicine. Its approach has the potential to create a new class of therapeutics for degenerative diseases.

AgingMusculoskeletalImmunologyNeurologyHematology

Technology Platform

Platform focused on developing small molecule inhibitors targeting the age-associated overactivation of the Cdc42 GTPase protein to rejuvenate stem cell function and combat age-related tissue degeneration.

Opportunities

The company operates in the high-growth longevity and regenerative medicine sector, targeting the root cause of multiple age-related diseases with a single platform, which offers a pipeline-in-a-product potential.

Successful validation of its Cdc42 inhibition approach could lead to partnerships with large pharma and address billion-dollar markets in osteoporosis, immune decline, and neurodegeneration.

Risk Factors

Major risks include the unproven translation of Cdc42 inhibition into safe and effective human therapies, the long and costly preclinical-to-clinical development path, and intense competition in the longevity space.

Financial dependency on future fundraising rounds and the challenge of defining clinical endpoints and regulatory pathways for healthspan extension are also significant hurdles.

Competitive Landscape

Mogling Bio competes in the rapidly evolving longevity biotech landscape, which includes companies targeting senescent cells (senolytics like Unity Biotechnology), mitochondrial function, and epigenetic reprogramming. Its specific focus on Cdc42 and stem cell rejuvenation is a key differentiator, but it must compete for funding, talent, and validation against these other mechanistic approaches to aging.

More companies in Small Molecule Drugs →More companies in United States →